Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Leases (2021 - 2025)

Crinetics Pharmaceuticals has reported Current Leases over the past 5 years, most recently at $6.5 million for Q4 2025.

  • Quarterly results put Current Leases at $6.5 million for Q4 2025, down 9.27% from a year ago — trailing twelve months through Dec 2025 was $6.5 million (down 9.27% YoY), and the annual figure for FY2025 was $6.5 million, down 9.27%.
  • Current Leases for Q4 2025 was $6.5 million at Crinetics Pharmaceuticals, up from $6.4 million in the prior quarter.
  • Over the last five years, Current Leases for CRNX hit a ceiling of $7.4 million in Q2 2024 and a floor of $939000.0 in Q4 2021.
  • Median Current Leases over the past 5 years was $5.8 million (2024), compared with a mean of $4.5 million.
  • Biggest five-year swings in Current Leases: skyrocketed 571.33% in 2024 and later dropped 13.11% in 2025.
  • Crinetics Pharmaceuticals' Current Leases stood at $939000.0 in 2021, then increased by 11.93% to $1.1 million in 2022, then soared by 297.05% to $4.2 million in 2023, then surged by 71.39% to $7.2 million in 2024, then dropped by 9.27% to $6.5 million in 2025.
  • The last three reported values for Current Leases were $6.5 million (Q4 2025), $6.4 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.